紫杉醇联合顺铂同步放化疗治疗术后食管癌52例

目的]探讨紫杉醇联合顺铂同步放化疗治疗术后食管癌的临床疗效。方法]2000年10月～2007年10月．52例根治术后的Ⅱ～Ⅲ期食管癌患者均接受紫杉醇联合顺铂化疗同步放疗．放疗剂量：50Gy／25F，5周。结果]28例（54％）患者发生了Ⅲ／Ⅳ级放化疗毒副反应，主要为白细胞下降／中性粒细胞减少、血小板减少和放射性食管炎。中位生存时间为37．2个月，1、3年生存率分别为82．19％、47．13％。2年局控率、无远处转移生存率和无进展生存率分别为60．01％、71．38％和42．01％。结论]同步放化疗治疗Ⅱ～Ⅲ期术后食管癌患者可行，毒副反应可耐受。

Concurrent Radiotherapy and Chemotherapy with Cisplatin plus Paclitaxel for 52 Cases with Esophageal Cancer Postoperation

Purpose] To investigate the clinical value of concurrent radiotherapy and chemotherapy with cisplatin plus paclitaxel for 52 cases with esophageal cancer postoperation. Methodsl From October 2000 to October 2007, 52 cases with stage Ⅱ～Ⅲ esophageal carcinoma undergoing radical operation received concurrent radiotherapy（50Gy/25F,5 weeks） and chemotherapy with cisplatin plus paclitaxel. Resultsl Twenty-eight cases （54%） experienced grade Ⅲ/Ⅳ toxicity mostly leukopenia/neutropenia, thrombocytopenia and radiation esophagitis. The median survival was 37.2 months, 1-year and 3-year survival were 82.19% and 47.13% respectively. The 2-year local-regional control survival, distant metastasis free survival and progression-free survival were 60.01%, 71.38% and 42.01% respectively. Conclusion] Concurrent radiotherapy and chemotherapy with cisplatin plus paelitaxel for postoperative esophageal cancer is feasible and tolerable.